Jeffrey E. Gershenwald, MD, FACS, is a professor of surgery in the department of surgical oncology and a professor in the department of cancer biology at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. He is also the medical director of the Melanoma and Skin Center, also at MDACC.
Dr. Gershenwald received his undergraduate degree from Cornell University and his medical degree from Cornell University Medical College. After completing his general surgery residency at The New York Hospital-Cornell Medical Center, Dr. Gershenwald completed a fellowship in surgical oncology at MDACC before joining the faculty there.
In addition to his active surgical oncology practice that focuses on the care of patients with melanoma, Dr. Gershenwald holds numerous academic administrative appointments. Dr. Gershenwald serves as a member of the Executive Committee of the American Joint Committee on Cancer (AJCC), chair of the AJCC Informatics Committee, and co-chair of the AJCC melanoma staging committee that recently revised the melanoma staging system. He is a co-director of the NIH-funded Melanoma SPORE and co-director of the Melanoma Informatics, Tissue Resource and Pathology Core, both at MDACC. Dr. Gershenwald’s research focuses on clinicopathological and molecular-based staging and prognostic assessment in melanoma and molecular mechanisms of melanoma progression. Dr. Gershenwald is a member of the Surgical Oncology Board of the American Board of Surgery and previously served as a member of the Executive Council and chair of the Training Committee of the Society of Surgical Oncology. More recently, Dr. Gershenwald has been a founding member and co-chair of the Melanoma Disease Working Group of The Cancer Genome Atlas (TCGA) project, MDACC lead for its melanoma TCGA tissue source site initiative, member of the Melanoma Research Foundation Breakthrough Consortium Steering Committee, and member of the Melanoma Research Alliance Medical Advisory Panel.
Dr. Gershenwald has published more than 155 articles in peer-reviewed journals, as well as more than 100 editorials, abstracts, invited articles and other publications. His many honors include the Physician-Scientist Program Award from MDACC, an American Cancer Society Research Scholar Grant Award to examine the “Biology and Significance of Melanoma Lymphatic Metastasis,” a Melanoma Research Alliance Team Science Award to study "Clinicopathological and Molecular Staging and Prognosis in Early-Stage Melanoma," and for the past 10 years, Dr. Gershenwald has been listed in America’s Best Doctors.